Market Challenges And Opportunities

Eisenmenger Syndrome Treatment Market Drivers

Continuous requirement of medication supports the growth of the Eisenmenger Syndrome Treatment Market. Eisenmenger Syndrome is a chronic disease and requires medication to be taken for a long period of time. The incidence and prevalence of Eisenmenger syndrome has not been properly defined due to the highly specific nature of the condition. However, according to National Center for Biotechnology Information (NCBI), 2010, an estimated 8% of patients with congenital heart disease are expected to develop Eisenmenger syndrome. According to Centers for Disease Control and Prevention (CDC), Congenital Heart Diseases affects nearly 1% or about 40,000 of the births per year in the U.S., 2018. Though technological and healthcare advancements have made it possible to correct congenital heart defects, the responses have been poor in case of patients suffering from Eisenmenger syndrome. Absence of treatment option which may cure the condition has fostered the growth of the global Eisenmenger syndrome treatment market, as physicians and patients have to rely on available therapies for the treatment. Most of the medications have generic versions available in the market, which has supported the growth of the market. Presence of disease targeting therapies such as Sildenafil and Bosentan have boosted the market growth over the past years and the trend is expected to remain the same, owing to unavailability of alternative options. Moreover, combination therapies is also expected to boost the growth of the market over the forecast period. European Society of Cardiology Consensus Guidelines, 2015, suggest the use of combination therapy (Sildenafil + Bosentan, and others) in the management of pulmonary hypertension. These factors are expected to boost growth of the market over forecast period.

Despite presence of disease targeting therapies such as Sildenafil, and Bosentan the survival prospects for patients suffering from Eisenmenger syndrome have continuously been low, and the prevalence of patients suffering from Eisenmenger syndrome has decreased in the developed economies such as North America and Europe. The main reason behind this is sophisticated surgical approach in the treatment in curing the congenital heart defects and fetal screening with echocardiography in early life for heart defects. Moreover, Actelion Pharmaceuticals, Ltd.’s drug Opsumit (macitentan) showed lower than expected results in the Phase 3 clinical trials in 2017. These factors are expected to restrain growth of the global Eisenmenger Syndrome Treatment Market.